A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Castle Biosciences Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 56,000 shares of CSTL stock, worth $1.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
56,000
Previous 12,400 351.61%
Holding current value
$1.59 Million
Previous $269,000 493.68%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$17.4 - $31.47 $1.05 Million - $1.9 Million
-60,369 Reduced 8.71%
633,016 $18.1 Million
Q2 2024

Aug 14, 2024

BUY
$18.84 - $24.94 $708,741 - $938,217
37,619 Added 5.74%
693,385 $15.1 Million
Q1 2024

May 15, 2024

BUY
$18.06 - $25.3 $5.91 Million - $8.27 Million
327,017 Added 99.47%
655,766 $14.5 Million
Q4 2023

Feb 14, 2024

SELL
$12.19 - $22.43 $2.31 Million - $4.25 Million
-189,309 Reduced 36.54%
328,749 $7.09 Million
Q3 2023

Nov 14, 2023

BUY
$13.28 - $20.3 $6.13 Million - $9.37 Million
461,775 Added 820.45%
518,058 $8.75 Million
Q2 2023

Aug 14, 2023

SELL
$11.66 - $26.0 $7.05 Million - $15.7 Million
-604,673 Reduced 91.48%
56,283 $772,000
Q1 2023

May 15, 2023

BUY
$19.47 - $28.49 $2.13 Million - $3.12 Million
109,641 Added 19.89%
660,956 $15 Million
Q4 2022

Feb 14, 2023

SELL
$18.08 - $30.0 $3.28 Million - $5.44 Million
-181,340 Reduced 24.75%
551,315 $13 Million
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $2.3 Million - $3.5 Million
102,059 Added 16.18%
732,655 $19.1 Million
Q2 2022

Aug 15, 2022

BUY
$16.0 - $45.99 $7.1 Million - $20.4 Million
443,589 Added 237.2%
630,596 $13.8 Million
Q1 2022

May 16, 2022

BUY
$33.17 - $46.98 $2.96 Million - $4.19 Million
89,121 Added 91.05%
187,007 $8.39 Million
Q4 2021

Feb 14, 2022

SELL
$39.06 - $67.58 $5.18 Million - $8.96 Million
-132,553 Reduced 57.52%
97,886 $4.2 Million
Q3 2021

Nov 15, 2021

BUY
$60.13 - $77.6 $10.2 Million - $13.2 Million
170,434 Added 284.03%
230,439 $15.3 Million
Q2 2021

Aug 16, 2021

SELL
$50.07 - $76.78 $4,356 - $6,679
-87 Reduced 0.14%
60,005 $4.4 Million
Q1 2021

May 17, 2021

BUY
$58.92 - $97.33 $2.95 Million - $4.88 Million
50,103 Added 501.58%
60,092 $4.11 Million
Q4 2020

Feb 16, 2021

SELL
$43.6 - $73.05 $2.17 Million - $3.64 Million
-49,807 Reduced 83.29%
9,989 $670,000
Q3 2020

Nov 16, 2020

SELL
$38.47 - $52.03 $61,782 - $83,560
-1,606 Reduced 2.62%
59,796 $3.08 Million
Q2 2020

Aug 14, 2020

BUY
$27.28 - $43.01 $1.68 Million - $2.64 Million
61,402 New
61,402 $2.32 Million
Q1 2020

May 15, 2020

SELL
$23.08 - $35.53 $205,411 - $316,217
-8,900 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$15.74 - $35.04 $342,738 - $762,996
-21,775 Reduced 70.99%
8,900 $305,000
Q3 2019

Nov 14, 2019

BUY
$18.09 - $27.92 $554,910 - $856,446
30,675 New
30,675 $554,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $748M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.